Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with <i>PIK3CA</i>-Mutated HR+/HER2– Advanced Breast Cancer
Anne Jacobson
Abstract
Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.
Topics & Concepts
MedicineLetrozoleFulvestrantOncologyInternal medicineBreast cancerHER2 negativeMetastatic breast cancerCancerGynecologyAromataseTamoxifenAdvanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer Research